<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Omega</journal-id><journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id><journal-id journal-id-type="publisher-id">ao</journal-id><journal-id journal-id-type="coden">acsodf</journal-id><journal-title-group><journal-title>ACS Omega</journal-title></journal-title-group><issn pub-type="epub">2470-1343</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7841949</article-id><article-id pub-id-type="doi">10.1021/acsomega.0c05581</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Indole-3-acetamides: As Potential Antihyperglycemic
and Antioxidant Agents; Synthesis, <italic>In Vitro</italic> &#x003b1;-Amylase
Inhibitory Activity, Structure&#x02013;Activity Relationship, and <italic>In Silico</italic> Studies</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Kanwal</surname><given-names/></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath2"><name><surname>Khan</surname><given-names>Khalid Mohammed</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Chigurupati</surname><given-names>Sridevi</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Ali</surname><given-names>Farman</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Younus</surname><given-names>Munissa</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Aldubayan</surname><given-names>Maha</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Wadood</surname><given-names>Abdul</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Khan</surname><given-names>Huma</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Taha</surname><given-names>Muhammad</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Perveen</surname><given-names>Shahnaz</given-names></name><xref rid="aff7" ref-type="aff">&#x02207;</xref></contrib><aff id="aff1"><label>&#x02020;</label>H.
E. J. Research Institute of Chemistry, International Center for Chemical
and Biological Sciences, <institution>University of Karachi</institution>, Karachi-75270, <country>Pakistan</country></aff><aff id="aff2"><label>&#x02021;</label><institution>Institute
of Marine Biotechnology, Universiti Malaysia Terengganu</institution>, 21030 Kuala Terengganu, Terengganu, <country>Malaysia</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Clinical Pharmacy, Institute for Research and Medical Consultations
(IRMC), <institution>Imam Abdulrahman Bin Faisal University</institution>, P.O. Box 1982, Dammam 31441, <country>Saudi Arabia</country></aff><aff id="aff4"><label>&#x02225;</label>Department
of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, <institution>Qassim University</institution>, Buraidah 52571, <country>Saudi Arabia</country></aff><aff id="aff5"><label>&#x022a5;</label>Department
of Pharmacology and Toxicology, College of Pharmacy, <institution>Qassim University</institution>, Buraidah 52571, <country>Saudi Arabia</country></aff><aff id="aff6"><label>#</label>Department
of Biochemistry, Computational Medicinal Chemistry Laboratory, UCSS, <institution>Abdul Wali Khan University</institution>, Mardan 23200, <country>Pakistan</country></aff><aff id="aff7"><label>&#x02207;</label><institution>PCSIR
Laboratories Complex, Karachi</institution>, Shahrah-e-Dr. Salimuzzaman Siddiqui, Karachi 75280, <country>Pakistan</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>khalid.khan@iccs.edu</email>, <email>drkhalidhej@gmail.com</email>. Tel: <phone>0092-21-34824910</phone>. Fax: <fax>0092-21-34819018</fax>.</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><day>26</day><month>01</month><year>2021</year></pub-date><volume>6</volume><issue>3</issue><fpage>2264</fpage><lpage>2275</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2021 The Authors. Published by American
Chemical Society</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Authors</copyright-holder><license><license-p>This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0012" id="ab-tgr1"/></p><p>Indole-3-acetamides
(<bold>1&#x02013;24</bold>) were synthesized
via coupling of indole-3-acetic acid with various substituted anilines
in the presence of coupling reagent 1,1-carbonyldiimidazole. The structures
of synthetic molecules were elucidated through different spectroscopic
techniques including electron ionization-mass spectroscopy (EI-MS), <sup>1</sup>H-, <sup>13</sup>C NMR, and high-resolution EI-MS (HREI-MS).
These compounds were screened for their antihyperglycemic and antioxidant
potentials. All compounds displayed good to moderate inhibition against
&#x003b1;-amylase enzyme with IC<sub>50</sub> values ranging between
1.09 &#x000b1; 0.11 and 2.84 &#x000b1; 0.1 &#x003bc;M compared to the standard
acarbose (IC<sub>50</sub> = 0.92 &#x000b1; 0.4 &#x003bc;M). Compound <bold>15</bold> (IC<sub>50</sub> = 1.09 &#x000b1; 0.11 &#x003bc;M) was the most
active compound of the series and exhibited good inhibition against
&#x003b1;-amylase; in addition, this compound also exhibited good antioxidant
potential with IC<sub>50</sub> values of 0.35 &#x000b1; 0.1 and 0.81
&#x000b1; 0.25 &#x003bc;M in 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH)
and 2,2&#x02032;-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS) assays, respectively. The binding interactions of synthetic
molecules with the enzyme&#x02019;s active site were confirmed via <italic>in silico</italic> studies. The current study had identified a number
of lead molecules as potential antihyperglycemic and antioxidant agents.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ao0c05581</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ao0c05581</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction:</title><p>Diabetes mellitus (DM), one of the common
metabolic disorders,
is usually characterized by irregular blood glucose levels. The elevated
level of blood glucose is referred to as hyperglycemia, which results
due to the abnormal functionality of enzyme insulin. Insulin is a
peptide hormone that is secreted through the islets of Langerhans.
Any damage to these cells leads to either less or no secretion of
insulin, which consequently leads to uncontrolled levels of glucose
in blood.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref3">3</xref></sup> There are many pathways through which diabetes can
be controlled, one of which is enzyme inhibition. Since digestive
enzymes such as &#x003b1;-amylase have been known to increase blood
glucose, one of the methods to control diabetes is the inhibition
of this enzyme for controlled digestion of carbohydrates in diabetic
patients.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> &#x003b1;-Amylase is an enzyme
(EC.3.2.1.1) that hydrolyzes &#x003b1;-1,4 glycoside bonds of complex
carbohydrate molecules such as starch and glycogen to yield glucose
and maltose. It contains calcium in its active site and is found in
normal serum, saliva, and urine of humans. It is also found in bacteria
and other living organisms. Primarily, &#x003b1;-amylase hydrolyzes
complex carbohydrate molecules into small oligosaccharides and maltodextrins,
and by the action of another digestive enzyme &#x003b1;-glucosidase,
they are finally converted to glucose and absorbed in the bloodstream.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Therefore, inhibition of &#x003b1;-amylase would
be an ideal therapy to control diabetes and its related complications.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Prolonged diabetes mainly affects the metabolism
of proteins, fats, carbohydrates, water, and electrolytes and thus
leads to various structural changes in tissues of vital organ systems
in the body, especially the vascular system.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> The increased level of blood glucose prompts several metabolic signaling
pathways that leads to inflammation, cytokines secretion, cell death,
and subsequently diabetic complications.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Therefore, diabetic patients are commonly found to be associated
with damage of heart, kidney, skin, eye, foot, etc. Alzheimer&#x02019;s
disease, a common neurological disorder, is also associated with prolonged
effects of this disease.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> The high prevalence
and rapid increase of diabetes have attracted the attention of many
researchers, and hence many drugs have been developed for its control
and cure. However, to date, no drug has been able to completely cure
this disease. Commercially available &#x003b1;-amylase inhibitors are
associated with a number of side effects, most commonly gastrointestinal
complications. Therefore, there is still a need and space for the
development of cheap and less harmful drugs that can be easily available
having potent antidiabetic activity.<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup></p><p>Among
many complications associated with DM, the formation of reactive
oxygen species (ROS) is also common and leads to severe damage of
many vital organs. A number of free radicals and reactive oxygen species
are formed during metabolism, and using antioxidants, these free radicals
are neutralized without any harmful effect to our body. Free radicals
may harm our immune system by a number of degenerative ailments. Free
radicals are chemically unstable species with unpaired electrons.
These unpaired electrons capture electrons from neighboring biomolecules
like DNA, proteins, and lipids, thus initiating chain reactions in
the body, which triggers the abnormal behavior of these biomolecules.<sup><xref ref-type="bibr" rid="ref11">11</xref>&#x02212;<xref ref-type="bibr" rid="ref15">15</xref></sup> Mitochondrial respiratory chain enzymes, <italic>e.g</italic>.,
xanthine oxidase, lipoxygenase, etc., affect the production of ROS
due to hyperglycemia.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Thus, a high level
of ROS and oxidative stress in diabetes leads to cellular death through
numerous mechanisms that finally leads to tissue damage.<sup><xref ref-type="bibr" rid="ref17">17</xref>&#x02212;<xref ref-type="bibr" rid="ref19">19</xref></sup> Therefore, diabetic complications can be controlled through the
downregulation of ROS generation.<sup><xref ref-type="bibr" rid="ref20">20</xref>&#x02212;<xref ref-type="bibr" rid="ref22">22</xref></sup></p><p>Indole belongs
to the class of heterocyclic compounds and possesses
a benzene ring fused with a pyrrole ring with a 10-electron system
from four double bonds and one nitrogen atom lone pair. It has been
used as a primary precursor molecule for the synthesis of a variety
of pharmaceuticals and fragrances.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> Indomethacin
and strychnine are among the most common biologically active synthetic
and natural product resources that are derived from indole.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Indole and its related compounds possess a wide
range of biological activities and are part of many medicinally important
nuclei, which were widely accepted as pharmacophores.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Currently, indole nucleus has been found to be a part of
more than 200 compounds that are marked as drugs or are undergoing
clinical trials.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Indoles are an important
class of compounds in the field of medicinal chemistry and found to
have different biological activities including anticancer, anti-inflammatory,
antiulcerogenic, antibacterial, antiviral, antifungal, etc.<sup><xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref></sup> Previously, our research group had explored and reported the potential
antihyperglycemic activity of different indole derivatives.<sup><xref ref-type="bibr" rid="ref32">32</xref>&#x02212;<xref ref-type="bibr" rid="ref35">35</xref></sup> Keeping in mind the antidiabetic potential of indoles, the synthetic
molecules were considered for their &#x003b1;-amylase inhibition and
antioxidant activity. The results showed that these compounds have
dual abilities of lowering the postprandial hyperglycemia and scavenging
the free radicals effectively and may serve as lead molecules in drug
discovery and development (<xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref> and <xref rid="fig2" ref-type="fig">2</xref>). To the best of our
knowledge, compounds <bold>1</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>13</bold> are reported in the literature and the remaining
compounds are new.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Rationale of the current study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0002" id="gr2" position="float"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>General
structure of synthetic compounds (<bold>1&#x02013;24</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0003" id="gr3" position="float"/></fig></sec><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Chemistry</title><p>Indole-3-acetamides
(<bold>1&#x02013;24</bold>) were synthesized via a one-pot multicomponent
reaction of indole-3-acetic
acid with 1,1-carbonyldiimidazole (CDI) and different substituted
anilines.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> First, indole-3-acetic acid
was allowed to react with CDI in the presence of catalytic amount
of pyridine in acetonitrile. Pyridine used in this reaction helps
in the deprotonation of carboxylic acid and makes it more feasible
to react with the coupling reagent. CO<sub>2</sub> gas evolved during
the reaction resulted in the formation of an intermediate A, which
was subsequently treated with different substituted anilines to afford
indole-3-acetamides. The synthetic analogues were purified and characterized
using different spectroscopic techniques including <sup>1</sup>H-, <sup>13</sup>C NMR, electron ionization-mass spectroscopy (EI-MS), and
high-resolution EI-MS (HREI-MS) (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title><italic>In Vitro</italic> &#x003b1;-Amylase
Inhibitory, DPPH, and ABTS Radical Scavenging Activities of Compounds <bold>1&#x02013;24</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0011" id="fx1" position="float"/><table-wrap-foot><fn id="t1fn1"><label>a</label><p>SEM is the standard error of the
mean, Acarbose<sup>(std)</sup> is the standard inhibitor for <italic>&#x003b1;</italic>-amylase inhibitory activity, and Ascorbic acid<sup>(std)</sup> is the standard inhibitor for 2,2-diphenyl-1-picryl-hydrazyl-hydrate
(DPPH) and 2,2&#x02032;-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid) (ABTS) activity.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.2"><title><italic>In Vitro</italic> &#x003b1;-Amylase Inhibitory Activity
and DPPH and ABTS Radical Scavenging Activities</title><p>Twenty-four
indole-3-acetamides <bold>1&#x02013;24</bold> were synthesized and
screened for antihyperglycemic and antioxidant activities. The molecules <bold>1&#x02013;24</bold> displayed good to moderate inhibition against
&#x003b1;-amylase enzyme with IC<sub>50</sub> values ranging between
1.09 &#x000b1; 0.11 and 2.84 &#x000b1; 0.1 &#x003bc;M. However, the antioxidant
potential was evaluated with DPPH and ABTS radical scavenging activities.
All synthetic derivatives potentially scavenged the reactive oxygen
species in the IC<sub>50</sub> value ranges of 0.35 &#x000b1; 0.1&#x02013;2.19
&#x000b1; 0.08 and 0.81 &#x000b1; 0.25&#x02013;2.75 &#x000b1; 0.03 &#x003bc;M
for ABTS and DPPH activities, respectively (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>).</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Synthesis of Indole-3-acetamides (<bold>1&#x02013;24</bold>)</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0010" id="gr1" position="float"/></fig></sec><sec id="sec2.3"><title>Structure&#x02013;Activity
Relationship for &#x003b1;-Amylase Inhibition</title><p>Limited structure&#x02013;activity
relationship suggested that compound <bold>1</bold> (IC<sub>50</sub> = 2.6 &#x000b1; 0.09 &#x003bc;M) bearing unsubstituted
phenyl ring demonstrated moderate inhibition against &#x003b1;-amylase
enzyme in comparison to the standard acarbose (IC<sub>50</sub> = 0.92
&#x000b1; 0.4 &#x003bc;M). The addition of methyl group at the <italic>para</italic> position of phenyl ring resulted in slightly reduced
activity in compound <bold>2</bold> (IC<sub>50</sub> = 2.84 &#x000b1;
0.1 &#x003bc;M). Compounds <bold>3</bold>, <bold>4</bold>, and <bold>5</bold> with dimethyl substitutions at different positions of aryl
ring displayed variable inhibitory activity. Among them, compound <bold>3</bold> (IC<sub>50</sub> = 2.52 &#x000b1; 0.06 &#x003bc;M) with <italic>meta</italic>- and <italic>para</italic>-substituted methyl groups
was moderately active. Changing the position of the methyl group from
meta to ortho resulted in decreased inhibitory activity in compound <bold>4</bold> (IC<sub>50</sub> = 2.68 &#x000b1; 0.08 &#x003bc;M). Nevertheless,
compound <bold>5</bold> (IC<sub>50</sub> = 2.38 &#x000b1; 0.1 &#x003bc;M)
with methyl groups para to each other showed superior activity among
methyl-substituted compounds. Thus, compounds with dimethyl substitution
were more active in comparison to mono methyl- and unsubstituted compounds <bold>1</bold> and <bold>2</bold>, which might be due to the better interaction
of methyl groups within the active site of enzyme. Nevertheless, compounds <bold>6</bold> (IC<sub>50</sub> = 2.42 &#x000b1; 0.07 &#x003bc;M) and <bold>7</bold> (IC<sub>50</sub> = 2.43 &#x000b1; 0.1 &#x003bc;M) with <italic>para</italic>-substituted ethyl and butyl groups, respectively, have
shown similar activity (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>SAR of alkyl-substituted compounds <bold>1&#x02013;7</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0004" id="gr4" position="float"/></fig><p>Compound <bold>8</bold> (IC<sub>50</sub> = 2.15
&#x000b1; 0.1 &#x003bc;M)
bearing <italic>para</italic> methoxy substituents displayed superior
activity to methyl-substituted derivatives. Compound <bold>9</bold> (IC<sub>50</sub> = 2.42 &#x000b1; 0.07 &#x003bc;M) having two methoxy
groups <italic>para</italic> to each other resulted in slightly decreased
inhibition. Replacing one of the methoxy groups with methyl and changing
their position in compound <bold>10</bold> (IC<sub>50</sub> = 2.24
&#x000b1; 0.06 &#x003bc;M) resulted in better inhibition compared to compound <bold>9</bold>. Interestingly, compound <bold>11</bold> (IC<sub>50</sub> = 2.63 &#x000b1; 0.1 &#x003bc;M) having <italic>para</italic>-substituted
butoxy group displayed similar activity to compound <bold>12</bold> (IC<sub>50</sub> = 2.64 &#x000b1; 0.1 &#x003bc;M) with octyloxy substitution
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>SAR of alkoxy-substituted
compounds <bold>8&#x02013;12</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0005" id="gr5" position="float"/></fig><p>Among halogen-substituted derivatives, compound <bold>13</bold> (IC<sub>50</sub> = 2.1 &#x000b1; 0.1 &#x003bc;M) bearing bromo group
at <italic>para</italic> substitution was slightly more active in
comparison to the <italic>meta</italic> bromo-substituted compound <bold>14</bold> (IC<sub>50</sub> = 2.27 &#x000b1; 0.04 &#x003bc;M). Compound <bold>15</bold> (IC<sub>50</sub> = 1.09 &#x000b1; 0.11 &#x003bc;M) having <italic>para</italic> fluoro group was the most active compound of this series,
which may be due to the inductive effect of the fluoro group. Changing
the position of the fluoro group from para to meta in compound <bold>16</bold> (IC<sub>50</sub> = 2.25 &#x000b1; 0.05 &#x003bc;M) resulted
in decreased inhibition. Nonetheless, compound <bold>17</bold> (IC<sub>50</sub> = 2.38 &#x000b1; 0.05 &#x003bc;M) with two fluoro atoms at ortho
and para positions, respectively, demonstrated moderate inhibition
in comparison to the standard acarbose, which was also found to be
less active than compound <bold>15</bold>, which showed that addition
of another fluoro atom resulted in increased inductive effect, thus
making it less available to bind with the active site of enzyme. Compound <bold>18</bold> (IC<sub>50</sub> = 2.20 &#x000b1; 0.08 &#x003bc;M) with changed
positions of the fluoro group also displayed similar activity to compound <bold>17</bold> (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>SAR of halogen-substituted compounds <bold>13&#x02013;18</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0006" id="gr6" position="float"/></fig><p>Compound <bold>19</bold> (IC<sub>50</sub> = 2.28
&#x000b1; 0.08 &#x003bc;M)
having a <italic>meta</italic>-substituted iodo group was less active
compared with the <italic>para</italic> iodo-substituted compound <bold>20</bold> (IC<sub>50</sub> = 2.14 &#x000b1; 0.08 &#x003bc;M). Compound <bold>21</bold> (IC<sub>50</sub> = 1.76 &#x000b1; 0.2 &#x003bc;M) with <italic>para</italic> chloro substitution was the second most active compound
of the series. Compound <bold>22</bold> (IC<sub>50</sub> = 2.33 &#x000b1;
0.09 &#x003bc;M) bearing chloro and methyl substituents para to each
other displayed weak inhibition in comparison to compound <bold>21</bold>. The decreased activity of this compound might be due to the addition
of methyl group and change in the position of the chloro group (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>).</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>SAR of halogen-substituted
compounds <bold>19&#x02013;22</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0007" id="gr7" position="float"/></fig><p>Compounds <bold>23</bold> (IC<sub>50</sub> = 2.48 &#x000b1; 0.06 &#x003bc;M)
and <bold>24</bold> (IC<sub>50</sub> = 2.15 &#x000b1; 0.09 &#x003bc;M)
with meta and para thiomethyl groups, respectively, also displayed
weak inhibition against &#x003b1;-amylase in comparison to standard
acarbose (IC<sub>50</sub> = 0.92 &#x000b1; 0.4 &#x003bc;M) (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>).</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>SAR of thiomethyl-substituted
compounds <bold>23&#x02013;24</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0008" id="gr8" position="float"/></fig></sec><sec id="sec2.4"><title>ABTS and DPPH Radical Scavenging Activities and Structure&#x02013;Activity
Relationships</title><p>Among 24 synthetic derivatives, the <italic>para</italic> flouro-substituted compound <bold>15</bold> was found
to exhibit superior ABTS and DPPH radical scavenging activities in
comparison to <italic>para</italic> chloro-, bromo-, and iodo-substituted
compounds <bold>21</bold>, <bold>13</bold>, and <bold>20</bold>, respectively.
It showed that the flouro group with a high negative inductive effect
and the smallest size among all halogen substituents was most active,
and an increased size of halogen atoms and decreased inductive effect
resulted in declined scavenging activity. Compounds <bold>14</bold>, <bold>16</bold>, and <bold>19</bold> with <italic>meta</italic> bromo, flouro, and iodo substituents, respectively, displayed similar
activities; nonetheless, these compounds were less active in comparison
to their <italic>para</italic>-substituted analogues. Compounds <bold>17</bold> and <bold>18</bold> bearing di-flouro substituents at ortho
para and meta para positions, respectively, also displayed decreased
activity in comparison to mono flouro-substituted compound <bold>15</bold>. This pattern showed that the number, nature, and positions of the
halogen groups play a crucial role in DPPH and ABTS radical scavenging
activities.</p><p>The methyl-substituted derivative <bold>2</bold> displayed weak antioxidant activity; nonetheless, the dimethyl-substituted
compounds <bold>3</bold>, <bold>4</bold>, and <bold>5</bold> showed
superior activity in comparison to compound <bold>2</bold>, which
might be due to the addition of another methyl group that resulted
in better activity due to the hyperconjugation effect. Compounds <bold>6</bold> and <bold>7</bold> with ethyl and butyl groups, respectively,
also displayed comparable activities to methyl-substituted compounds.
Compound <bold>8</bold> bearing a methoxy group displayed better activity
than methyl-substituted compounds. However, dimethoxy-substituted
compound <bold>9</bold> was less active than compound <bold>8</bold>. The general activity pattern revealed that compounds with halogen
substitutions were better antioxidizing agents compared to methyl
and methoxy.</p><p>Hyperglycemia has many adverse effects along with
the promotion
of auto-oxidation of glucose to form free radicals. The antioxidant
defense system is capable of scavenging a particular amount of free
radicals; thus, the excessive production of free radicals results
in macro- and microvascular dysfunction and polyneuropathy. Therefore,
the drugs that can effectively scavenge the free-radical formation
would be a preferable therapeutic strategy to prevent oxidative stress
and the related diabetic vascular complications. Since the synthetic
molecules (<bold>1&#x02013;24</bold>) were capable of inhibiting the
activity of &#x003b1;-amylase enzyme as well as free radicals, these
molecules might act as lead candidates for drug discovery and research.
Further research and modifications in the structures of these molecules
might be helpful for the discovery of new drug molecules.</p></sec><sec id="sec2.5"><title>Molecular Docking
study</title><p><italic>In silico</italic> docking
simulation was conducted to explore the binding modes of indole-3-acetamide
derivatives <bold>1&#x02013;24</bold> against &#x003b1;-amylase enzyme.
The crystal structure of &#x003b1;-amylase (PDB ID: 1HNY) was downloaded
from Protein Data Bank for docking study. Docking simulation was performed
by MOE-2016 software. Using the default parameters of MOE, the &#x003b1;-amylase
enzyme and the newly synthesized compounds were protonated and energy-minimized
to get the optimized structures of the protein and compounds. These
optimized structures of target protein and compounds were further
used for docking studies.</p></sec><sec id="sec2.6"><title>Docking Results Analysis</title><p>The docking
study was used
to explore the binding interactions of the ligand molecules into &#x003b1;-amylase
active-site residues. At the end of docking simulation, the binding
interactions of all of the 24 compounds were discussed and their 3D
images were taken. From the docking study, it was revealed that the
docked conformations of all of the compounds are appropriately oriented
toward the catalytic residues, making sufficient interactions with
the active-site residues Trp58, Trp59, Tyr62, Leu162, Arg195, Asp197,
Glu233, Asp300, and His305 of the target enzyme.</p><sec id="sec2.6.1"><title>Interactions of the Halides
Containing Compounds</title><p>Compounds <bold>13</bold>&#x02013;<bold>22</bold> are grouped as halide-containing
compounds. All of these compounds have the same 2-(1<italic>H</italic>-indol-3-yl)-<italic>N</italic>-phenylacetamide group, whereas the
phenyl ring contains different halide groups. According to the IC<sub>50</sub> value, compound <bold>15</bold> (1.09 &#x000b1; 0.11 &#x003bc;M)
is the most active compound of this group. It is clear from <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>a that compound <bold>15</bold> was bound deeply into the binding cavity of &#x003b1;-amylase
showing four interactions with the residues Leu165, Ala198, His201,
and Asp300. The hydrogen bond was observed between Asp300 and the
indole moiety of compound <bold>15</bold>, whereas the aromatic rings
of the compound show &#x003c0;&#x02013;H interactions with the Leu165,
Ala198, and His201 residues of the protein.</p><fig id="fig8" position="float"><label>Figure 8</label><caption><p>3D pose of docked conformations
of compounds <bold>15</bold> (a), <bold>21</bold> (b), <bold>8</bold> (c), and <bold>24</bold> (d) (purple)
in the active site of <italic>&#x003b1;</italic>-amylase enzyme (red).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_0009" id="gr9" position="float"/></fig><p>Compound <bold>21</bold> is the second most active
compound (IC<sub>50</sub> = 1.76 &#x000b1; 0.2 &#x003bc;M) in this group,
forming three
prominent hydrogen bonds with the binding-site residues Arg195, His299,
and Asp300, as shown in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>b.</p><p>The key structural feature observed in this group
for good interaction
mode and active nature of compounds is the presence of an electron-withdrawing
group like halogen groups at specific positions on the phenyl ring.</p></sec><sec id="sec2.6.2"><title>Interactions of the Alkoxy- and Methanethiol-Containing Compounds</title><p>To discuss the interaction details, compounds <bold>8</bold>&#x02013;<bold>12</bold> were placed in the second group due to the presence of
the alkoxy group on the phenyl ring. Compound <bold>8</bold> is the
most active compound (IC<sub>50</sub> = 2.15 &#x000b1; 0.1 &#x003bc;M)
in this group that shows hydrogen bonding with Glu233 and &#x003c0;&#x02013;H
interactions with Trp59 and Leu162, as shown in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>c.</p><p>However, compounds <bold>23</bold> and <bold>24</bold> have a common methanethiol group on the phenyl
ring with different <italic>meta</italic> and <italic>para</italic> positions. Compound <bold>11</bold> was observed in making good
interactions with active-site residues Glu233, Trp59, and leu162 (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>d). Compound <bold>23</bold> shows higher activity (IC<sub>50</sub> = 2.15 &#x000b1; 0.09
&#x003bc;M) than compound <bold>24</bold>. It may due to the <italic>para</italic> position of the methanethiol group, which is the activating
group.</p></sec><sec id="sec2.6.3"><title>Interactions of the Alkyl-Containing Compounds</title><p>Compounds <bold>1&#x02013;7</bold> contain alkyl groups on the phenol moiety of the
acetamide core structure at various ortho, meta, and para positions.
Compound <bold>22</bold> of this group containing chloro-methylphenyl
group shows the best activity (IC<sub>50</sub> = 2.33 &#x000b1; 0.09
&#x003bc;M) against &#x003b1;-amylase enzyme. The NH group of the indole
moiety of the compound makes a hydrogen bond with Asp300, and the
phenol ring shows &#x003c0;&#x02013;&#x003c0; interaction with Trp59 active-site
residues. The activity may be due to the presence of chloro-methylphenyl
moiety <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Interaction Details, Docking Score
Binding Energy, and Binding Affinity of the Compound Docked in the
Active Site of &#x003b1;-Amylase Enzyme</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">C. no.</th><th style="border:none;" align="center" char=".">docking score</th><th style="border:none;" align="center" char=".">binding
energy (kcal/mol)</th><th style="border:none;" align="center" char=".">binding affinity (kcal/mol)</th><th style="border:none;" align="center">interaction detail (ligands/&#x003b1;-amylase)</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.548</td><td style="border:none;" align="char" char=".">25.16</td><td style="border:none;" align="char" char=".">&#x02013;5.29</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 H-donor 3.00</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD2 ASP 300 H-donor
3.24</td></tr><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.777</td><td style="border:none;" align="char" char=".">&#x02013;27.14</td><td style="border:none;" align="char" char=".">&#x02013;5.66</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD2 ASP 300 H-donor 2.94</td></tr><tr><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.466</td><td style="border:none;" align="char" char=".">&#x02013;26.78</td><td style="border:none;" align="char" char=".">&#x02013;5.30</td><td style="border:none;" align="left">ligand&#x02013;receptor@@
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 H-donor 3.05</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring 5-ring TRP 59 pi-pi 3.58</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring 6-ring
TRP 59 pi-pi 3.99</td></tr><tr><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.767</td><td style="border:none;" align="char" char=".">&#x02013;27.90</td><td style="border:none;" align="char" char=".">&#x02013;5.61</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 H-donor 2.97</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD2 ASP 300 H-donor
3.26</td></tr><tr><td style="border:none;" align="left"><bold>5</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.814</td><td style="border:none;" align="char" char=".">&#x02013;28.06</td><td style="border:none;" align="char" char=".">&#x02013;5.62</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 H-donor 3.05</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD2 ASP 300 H-donor 3.00</td></tr><tr><td style="border:none;" align="left"><bold>6</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.165</td><td style="border:none;" align="char" char=".">&#x02013;29.75</td><td style="border:none;" align="char" char=".">&#x02013;5.81</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction
distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 197 (A) H-donor 3.02</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">5-ring CB ALA 198 (A) pi-H 4.67</td></tr><tr><td style="border:none;" align="left"><bold>7</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.468</td><td style="border:none;" align="char" char=".">&#x02013;30.35</td><td style="border:none;" align="char" char=".">&#x02013;6.15</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">5-ring CB TYR 62 pi-H 4.04</td></tr><tr><td style="border:none;" align="left"><bold>8</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.6</td><td style="border:none;" align="char" char=".">&#x02013;34.41</td><td style="border:none;" align="char" char=".">&#x02013;5.98</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OE1 GLU 233 H-donor 2.4</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring CB TRP
59 pi-H 3.3</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring CD1 LEU 162 pi-H 3.6</td></tr><tr><td style="border:none;" align="left"><bold>9</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.685</td><td style="border:none;" align="char" char=".">&#x02013;26.76</td><td style="border:none;" align="char" char=".">&#x02013;5.41</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 (A) H-donor
3.10</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD2 ASP 300 (A) H-donor 2.94</td></tr><tr><td style="border:none;" align="left"><bold>10</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.296</td><td style="border:none;" align="char" char=".">&#x02013;35.44</td><td style="border:none;" align="char" char=".">&#x02013;6.28</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 20 OD1 ASP 300 H-donor 3.18</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">5-ring CB TRP 59 pi-H 3.87</td></tr><tr><td style="border:none;" align="left"><bold>11</bold></td><td style="border:none;" align="char" char=".">&#x02013;6.48</td><td style="border:none;" align="char" char=".">&#x02013;33.37</td><td style="border:none;" align="char" char=".">&#x02013;6.32</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 H-donor 3.04</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD2 ASP 300
H-donor 3.11</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">C 13 6-ring TYR 62 H-pi 4.22</td></tr><tr><td style="border:none;" align="left"><bold>12</bold></td><td style="border:none;" align="char" char=".">&#x02013;6.756</td><td style="border:none;" align="char" char=".">&#x02013;38.25</td><td style="border:none;" align="char" char=".">&#x02013;6.92</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left"><bold>12</bold></td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OE2 GLU 240
H-donor 3.08</td></tr><tr><td style="border:none;" align="left"><bold>13</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.135</td><td style="border:none;" align="char" char=".">&#x02013;29.03</td><td style="border:none;" align="char" char=".">&#x02013;5.80</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 197 H-donor 2.91</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">BR 33 OD2 ASP 356 H-donor
3.2</td></tr><tr><td style="border:none;" align="left"><bold>14</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.212</td><td style="border:none;" align="char" char=".">&#x02013;28.85</td><td style="border:none;" align="char" char=".">&#x02013;5.99</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">O 22 CE1 HIS 201 H-acceptor 3.23</td></tr><tr><td style="border:none;" align="left"><bold>15</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.625</td><td style="border:none;" align="char" char=".">&#x02013;27.84</td><td style="border:none;" align="char" char=".">&#x02013;5.61</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance N 11 OD2 ASP 300
H-donor 1.74</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring CD2 LEU 165 pi-H 2.8</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">5-ring CB ALA 198 pi-H 3.13</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring CE1 HIS 201 pi-H
3.95</td></tr><tr><td style="border:none;" align="left"><bold>16</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.444</td><td style="border:none;" align="char" char=".">&#x02013;27.69</td><td style="border:none;" align="char" char=".">&#x02013;5.73</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 197 H-donor 2.99</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring CD1 LEU 162 pi-H 4.79</td></tr><tr><td style="border:none;" align="left"><bold>17</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.35</td><td style="border:none;" align="char" char=".">&#x02013;25.44</td><td style="border:none;" align="char" char=".">&#x02013;5.06</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction
distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 H-donor 3.08</td></tr><tr><td style="border:none;" align="left"><bold>18</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.066</td><td style="border:none;" align="char" char=".">&#x02013;31.00</td><td style="border:none;" align="char" char=".">&#x02013;5.78</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction
distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 20 OD1 ASP 300 H-donor 3.09</td></tr><tr><td style="border:none;" align="left"><bold>19</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.331</td><td style="border:none;" align="char" char=".">&#x02013;28.92</td><td style="border:none;" align="char" char=".">&#x02013;5.81</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction
distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">I 33 OD2 ASP 356 H-donor 3.91</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">5-ring CB ALA 198 pi-H 4.70</td></tr><tr><td style="border:none;" align="left"><bold>20</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.221</td><td style="border:none;" align="char" char=".">&#x02013;31.46</td><td style="border:none;" align="char" char=".">&#x02013;5.89</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 20 OD1 ASP 300 H-donor 2.89</td></tr><tr><td style="border:none;" align="left"><bold>21</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.6</td><td style="border:none;" align="char" char=".">&#x02013;32.31</td><td style="border:none;" align="char" char=".">&#x02013;5.99</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction
distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 20 OD1 ASP 300 H-donor 1.75</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">O 22 NH2 ARG 195 H-acceptor 1.89</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">O 22 NE2 HIS 299
H-acceptor 2.00</td></tr><tr><td style="border:none;" align="left"><bold>22</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.807</td><td style="border:none;" align="char" char=".">&#x02013;32.81</td><td style="border:none;" align="char" char=".">&#x02013;6.40</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD1 ASP 300 H-donor 3.02</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring 5-ring TRP 59
pi-pi 3.71</td></tr><tr><td style="border:none;" align="left"><bold>23</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.683</td><td style="border:none;" align="char" char=".">&#x02013;26.56</td><td style="border:none;" align="char" char=".">&#x02013;5.48</td><td style="border:none;" align="left">ligand&#x02013;receptor interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OD2 ASP 300 H-donor 3.07</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">C 13 6-ring TYR 62 H-pi
4.15</td></tr><tr><td style="border:none;" align="left"><bold>24</bold></td><td style="border:none;" align="char" char=".">&#x02013;5.658</td><td style="border:none;" align="char" char=".">&#x02013;32.99</td><td style="border:none;" align="char" char=".">&#x02013;5.75</td><td style="border:none;" align="left">ligand&#x02013;receptor
interaction distance</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">N 11 OE1 GLU 233 H-donor 2.5</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring CB TRP 59 pi-H 3.4</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">6-ring CD1 LEU
162 pi-H 3.6</td></tr></tbody></table></table-wrap><p>Overall, the whole series of 2-(1<italic>H</italic>-indol-3-yl)-<italic>N</italic>-phenylacetamide derivatives shows the best activity against
&#x003b1;-amylase enzyme. Different groups like halides, methanethiol,
alkyl, and alkoxy groups at various positions of the phenol ring of
the phenylacetamide compound may be responsible for their best inhibitory
activity against &#x003b1;-amylase enzyme. Details about the interaction
and docking of these compounds are given in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>.</p></sec></sec></sec><sec id="sec3"><title>Conclusions</title><p>Indole-3-acetamides
(<bold>1&#x02013;24</bold>) were synthesized
and evaluated for &#x003b1;-amylase inhibition along with antioxidant
activity. All synthetic compounds displayed good inhibition against
&#x003b1;-amylase. The synthetic molecules are also found to have good
antioxidant potential. Among 24 derivatives, compounds <bold>6</bold>, <bold>11</bold>, <bold>15</bold>, and <bold>18</bold> were found
to exhibit potential inhibition compared to the standard acarbose
(IC<sub>50</sub> = 0.92 &#x000b1; 0.40 &#x003bc;M). The molecular docking
studies identified the types of binding interactions, which helped
the synthetic compounds to interact within the active site of enzyme.
Thus, this study identified many lead candidates that can act as potential
antidiabetic and antioxidant agents.</p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>Materials
and Methods</title><p>Thin-layer chromatography (TLC)
was carried out on precoated silica gel, GF-254 (Merck, Germany).
Spots were visualized under ultraviolet light at 254 and 366 nm. EI-MS
and HREI-MS spectra were recorded on MAT 312 and MAT 113D mass spectrometers. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker
Avance AM spectrometer operating at 300 MHz. The chemical shift values
are presented in ppm (d), relative to tetramethylsilane (TMS) as an
internal standard, and the coupling constants (<italic>J</italic>)
are in hertz. The melting points of the compounds were determined
on a Stuart SMP10 melting point apparatus and are uncorrected.</p></sec><sec id="sec4.2"><title>General
Procedure for the Synthesis of Indole-3-acetamides (1&#x02013;24)</title><p>Indole-3-acetic acid (0.175 g, 1 mmol), pyridine (0.8 mL), and
CDI 1 equivalent (0.168 g) were taken in a reaction flask along with
acetonitrile (20 mL) and stirred for 45 min at room temperature. The
corresponding anilines were then added to the reaction mixture, and
the mixture was continuously stirred for 2&#x02013;24 h. The reaction
was monitored with TLC, and the products were obtained by extraction
with dichloromethane. The product was then washed with hexane to get
pure product.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup></p></sec><sec id="sec4.3"><title>&#x003b1;-Amylase Inhibition
Assay</title><p>The activity was performed
through modified assay from Kwon, Apostolidis, and Shetty.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> Phosphate buffer (0.2 mM, pH 6.9) in 500 &#x003bc;L of &#x003b1;-amylase
solution obtained from <italic>Aspergillus oryzae</italic> (0.5 mg/mL) was incubated with 500 &#x003bc;L of test sample (100,
200, 400, 800, 1000 &#x003bc;g/mL) at 25 &#x000b0;C for 10 min. Sodium
phosphate buffer (0.02 M, pH 6.9) with 1% starch solution (500 &#x003bc;L)
was added to each tube and further incubated for 10 min at 25 &#x000b0;C.
The reaction mixture was then incubated in boiling water for 5 min
after addition of 1 mL of dinitrosalicylic acid. The reaction mixture
was then cooled to room temperature. The absorbance was measured at
540 nm after the addition of 10 mL of distilled water. The percentage
inhibition was calculated as illustrated<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05581_m001" position="anchor"/></disp-formula></p></sec><sec id="sec4.4"><title>Molecular Docking Studies</title><p><italic>In silico</italic> docking
simulation was conducted to explore the binding modes of
indole-3-acetamide derivatives against &#x003b1;-amylase enzyme. The
crystal structure of &#x003b1;-amylase (PDB ID: 1HNY) was downloaded
from Protein Data Bank for docking study. Docking simulation was performed
by MOE-2016 software. Using the default parameters of MOE, the &#x003b1;-amylase
enzyme and the newly synthesized compounds were protonated and energy-minimized
to get the optimized structures of the protein and compounds. These
optimized structures of target protein and compounds were further
used for docking studies.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup></p></sec><sec id="sec4.5"><title>Spectral Data
of Synthetic Compounds (<bold>1&#x02013;24</bold>)</title><sec id="sec4.5.1"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-phenylacetamide
(<bold>1</bold>)</title><p>Yield: 78%; mp: 186&#x02013;188 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.14 (s, 1H, NH), 9.04 (s, 1H, NH), 7.62(m, 3H, H-4&#x02032;, H-2&#x02032;,
H-6&#x02032;), 7.38 (d, <italic>J</italic><sub>4,5</sub> = 8.1 Hz,
1H, H-4), 7.32 (s, 1H, H2), 7.24 (t, <italic>J</italic> = 8.4 Hz,
2H, H-3&#x02032;, H-5&#x02032;), 7.11 (m, 1H, H-6), 7.03 (m, 2H, H-5,
H-7), 3.80 (s, 2H, H-2&#x02033;); <sup>13</sup>C NMR (300 MHz, dimethyl
sulfoxide (DMSO)-<italic>d</italic><sub>6</sub>): &#x003b4; 169.6, 139.3,
136.0, 128.6, 127.1, 123.8, 122.9, 120.9, 119.0, 118.6, 118.3, 111.3,
108.5, 33.7; EI-MS <italic>m/z</italic> (% rel. abund.): 250 (M<sup>+</sup>, 82.6), 157 (22), 130 (100), 103 (57), 93 (54), 77 (70);
HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O [250.1106], found [250.1095].</p></sec><sec id="sec4.5.2"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(<italic>p</italic>-tolyl)
acetamide (<bold>2</bold>)</title><p>Yield: 21%;
mp: 187&#x02013;188 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.12 (s, 1H, NH), 8.94 (s, 1H,
NH), 7.64 (d, <italic>J</italic> = 7.8 Hz, 1H, H-4), 7.47 (d, <italic>J</italic> = 8.4 Hz, 2H, H-2&#x02032;, H-6&#x02032;), 7.38 (d, <italic>J</italic> = 7.8 Hz, 1H, H-7), 7.31 (s, 1H, H-2), 7.04 (m, 4H, H-3&#x02032;,
H-5&#x02032;, H-5, H-6), 3.78 (s, 2H, H-2&#x02033;), 2.22 (s, 3H, CH<sub>3</sub>), <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 169.4, 136.8, 136.0, 131.8, 128.9, 127.2, 123.7,
120.9, 119.0, 118.6, 118.3, 111.3, 108.6, 33.7, 20.3, EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 264 (M<sup>+</sup>, 80), 131 (53), 130 (100).</p></sec><sec id="sec4.5.3"><title><italic>N</italic>-(3,4-Dimethylphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide (<bold>3</bold>)</title><p>Yield:
89%; mp: 158&#x02013;160
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.12 (s, 1H, NH), 8.82 (s, 1H, NH), 7.63 (d, <italic>J</italic> = 8.1 Hz, 1H, H-4), 7.36 (m, 4H, H-5&#x02032;, H-6&#x02032;,
H-2, H-7), 7.10 (t, <italic>J</italic> = 7.2 Hz, 1H, H-5), 7.01 (m,
2H, H-6, H-2&#x02032;), 3.77 (s, 2H, H-2&#x02033;), 2.14 (s, 6H, CH<sub>3</sub>), <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 169.3, 137.0, 136.1, 136.0, 130.6, 129.4, 127.1,
123.7, 120.9, 120.3, 118.6, 118.3, 116.5, 111.2, 108.6, 33.7, 19.5,
18.6, EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.):
278 (M<sup>+</sup>, 57), 131 (34), 130 (100), 121 (25), HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O [278.1419], found [278.1431].</p></sec><sec id="sec4.5.4"><title><italic>N</italic>-(2,4-Dimethylphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>4</bold>)</title><p>Yield: 51%; mp: 142&#x02013;144
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.22 (s, 1H, NH), 8.22 (s, 1H, NH), 7.68 (d, <italic>J</italic> = 7.8 Hz, 1H, H-4), 7.44 (m, 3H, H-2, H-5&#x02032;, H-7),
7.12 (t, <italic>J</italic> = 7.8 Hz, 1H, H-5), 7.01 (m, 2H, H-6,
H-3&#x02032;), 6.90 (d, <italic>J</italic> = 7.2 Hz, 1H, H-6&#x02032;),
3.84 (s, 2H, H-2&#x02033;), 2.82 (s, 3H, CH<sub>3</sub>), 1.84 (s,
3H, CH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub><italic>6</italic></sub>): &#x003b4; 169.6, 136.7, 136.2, 136.1,
130.8, 127.1, 126.6, 125.0, 123.8, 123.2, 120.9, 118.6, 118.3, 111.3,
108.7, 38.3, 38.1, 33.0; EI-MS <italic>m/z</italic> (% rel. abund.):
278 (M<sup>+</sup>, 93), 131 (52), 130 (100), 121 (25); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O [278.1419], found [278.1422].</p></sec><sec id="sec4.5.5"><title><italic>N</italic>-(2,5-Dimethylphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>5</bold>)</title><p>Yield: 53%; mp: 151&#x02013;153
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 10.24 (s, 1H, NH), 8.08 (s, 1H,
NH), 7.65 (m, 2H, H-6&#x02032;, H-2), 7.42 (d, <italic>J</italic> =
6.3 Hz, 2H, H-7, H-4), 7.12 (t, <italic>J</italic> = 7.2 Hz, 1H, H-5),
7.04 (t, <italic>J</italic> = 7.5 Hz, 1H, H-6), 6.94 (d, <italic>J</italic><sub>&#x02032;</sub> = 7.5 Hz, 1H, H-3&#x02032;), 6.78 (d, <italic>J</italic> = 7.5 Hz, 1H, H-4&#x02032;), 3.84 (s, 2H, H-2&#x02033;),
2.23 (s, 3H, CH<sub>3</sub>), 1.85 (s, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub><italic>6</italic></sub>): &#x003b4; 169.4, 136.2, 136.1, 134.8, 129.9, 128.0, 127.1, 125.5,
125.1, 123.8, 120.9, 118.5, 118.3, 111.3, 108.7, 33.1, 20.5, 17.1;
EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 278 (M<sup>+</sup>, 58), 131 (22), 130 (100), 121 (11), HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O [278.1419], found [278.1408].</p></sec><sec id="sec4.5.6"><title><italic>N</italic>-(4-Ethylphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>6</bold>)</title><p>Yield: 42%; mp: 160&#x02013;162 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone- <italic>d</italic><sub>6</sub>):
&#x003b4; 10.11 (s, 1H, NH), 8.93 (s, 1H, NH),7.63 (d, <italic>J</italic> = 7.8 Hz, 1H, H-4), 7.50 (d, <italic>J</italic> = 8.4 Hz, 2H, H-2&#x02032;,
H-6&#x02032;), 7.38 (d, <italic>J</italic> = 7.8 Hz, 1H, H-7), 7.32
(s, 1H, H-2), 7.08 (m, 3H, H-3&#x02032;, H-5&#x02032;, H-5), 7.01 (t, <italic>J</italic> = 7.5 Hz, 1H, H-6), 3.78 (s, 2H, H-2&#x02033;), 2.54 (m,
2H, CH<sub>2</sub>), 1.15 (t, <italic>J</italic> = 7.5 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 169.4, 138.3, 137.0, 136.0, 127.8, 127.1, 123.7,
120.9, 119.1, 118.6, 118.3, 111.3, 108.6, 33.7, 27.5, 15.6; EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 278 (M<sup>+</sup>, 33), 157 (5), 130 (100); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O [278.1419],
found [278.1400].</p></sec><sec id="sec4.5.7"><title><italic>N</italic>-(4-Butylphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>7</bold>)</title><p>Yield: 97%; mp: 141&#x02013;143 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.13 (s, 1H, NH), 8.95 (s, 1H, NH), 7.63 (d, <italic>J</italic> =
7.5 Hz, 1H, H-4), 7.50 (d, <italic>J</italic> = 8.7 Hz, 2H, H-2&#x02032;,
H-6&#x02032;), 7.38 (d, <italic>J</italic> = 8.1 Hz, 1H, H-7), 7.32
(s, 1H, H-2), 7.06 (m, 4H, H-5, H-6, H-3&#x02032;,H-5&#x02032;), 3.78
(s, 2H, H-2&#x02033;), 2.53 (t, <italic>J</italic> = 7.5 Hz, 2H, CH<sub>2</sub>), 1.52 (m, 2H, CH<sub>2</sub>), 1.29 (m, 2H, CH<sub>2</sub>), 0.88 (t, <italic>J</italic> = 7.5 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4;
169.4, 137.0, 136.9, 136.0, 128.3, 127.1, 123.7, 120.9, 119.0, 118.6,
118.3, 111.3, 108.6, 34.1, 33.7, 33.1, 21.6, 13.7; EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 306 (M<sup>+</sup>, 86), 130
(100), 106 (33); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd
for C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O [306.1732], found [306.1699].</p></sec><sec id="sec4.5.8"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(4-methoxyphenyl)acetamide
(<bold>8</bold>)</title><p>Yield: 81%; M.p.: 184-185 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, Acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.12 (s, 1H, NH), 8.88 (s, 1H, NH), 7.64 (d, <italic>J</italic> =
7.8 Hz, 1H, H-4), 7.50 (d, <italic>J</italic> = 9.0 Hz, 2H, H-2&#x02032;,
H-6&#x02032;), 7.38 (d, <italic>J</italic> = 7.8 Hz, 1H, H-7), 7.31
(s, 1H, H-2), 7.10 (t, <italic>J</italic> = 7.5 Hz, 1H, H-5), 7.00
(t, <italic>J</italic> = 7.2 Hz, 1H, H-6), 6.80 (d, <italic>J</italic> = 9.0 Hz, 2H, H-3&#x02032;, H-5&#x02032;), 3.76 (s, 2H, H-2&#x02033;),
3.72 (s, 3H, OCH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 169.1, 155.0, 136.0, 132.5, 127.2,
123.7, 120.9, 120.5, 118.6, 118.3, 113.7, 111.3, 108.6, 55.1, 33.6;
EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 280 (M<sup>+</sup>, 27), 130 (100), 108 (10), HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [280.1212], found [280.1194].</p></sec><sec id="sec4.5.9"><title><italic>N</italic>-(2,5-Dimethoxyphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide (<bold>9</bold>)</title><p>Yield:
35%; mp: 152&#x02013;154
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.27 (s, 1H, NH), 8.37 (s, 1H, NH), 8.08 (d, <italic>J</italic> = 3 Hz, 1H, H-6&#x02032;), 7.63 (d, <italic>J</italic> =
8.1 Hz, 1H, H-3&#x02032;), 7.45 (s, 1H, H-2), 7.42 (m, 1H, H-4), 7.16
(m, 1H, H-5), 7.05 (m, 1H, H-6), 6.77 (d, <italic>J</italic> = 8.7
Hz, 1H, H-7), 6.48 (dd, <italic>J</italic><sub>4&#x02032;,6&#x02032;</sub> = 3 Hz, <italic>J</italic><sub>4&#x02032;,3&#x02032;</sub> = 3 Hz,
1H, H-4&#x02032;), 3.87 (s, 2H, H-2&#x02033;), 3.69 (s, 3H, OCH<sub>3</sub>), 3.49 (s, 3H, OCH<sub>3</sub>); <sup>13</sup>C NMR (300
MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 170.1, 154.7,
143.1, 137.8, 130.0, 128.2, 125.2, 122.5, 1119.9, 119.4, 112.3, 112.1,
109.4, 107.7, 106.7; EI-MS <italic>m</italic>/<italic>z</italic> (%
rel. abund.): 310 (M<sup>+</sup>, 61), 153 (24), 138 (25), 130 (100);
HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> [310.1317], found [310.1314].</p></sec><sec id="sec4.5.10"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(3-methoxy-4-methylphenyl)acetamide
(<bold>10</bold>)</title><p>Yield: 33%; mp: 102&#x02013;104 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.12 (s, 1H, NH), 8.95 (s, 1H, NH), 7.64 (d, <italic>J</italic> =
7.8 Hz, 1H, H-4), 7.38 (d, <italic>J</italic> = 7.5 Hz, 2H, H-7, H-6&#x02032;),
7.32 (s, 1H, H-2), 7.11 (t, <italic>J</italic> = 7.2 Hz, 1H, H-5),
7.02 (m, 3H, H-2&#x02032;, H-5&#x02032;, H-6), 3.78 (s, 2H, H-2&#x02033;),
3.73 (s, 3H, OCH<sub>3</sub>), 2.04 (m, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4;
169.5, 157.1, 138.5, 136.0, 130.0, 127.2, 123.8, 120.9, 119.9, 118.6,
118.3, 111.3, 110.5, 108.5, 101.8, 54.9, 33.8, 15.5; EI-MS <italic>m/z</italic> (% rel. abund.): 294 (M<sup>+</sup>, 34), 157 (5), 130
(100), 77 (8); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd
for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [294.1368],
found [294.1381].</p></sec><sec id="sec4.5.11"><title><italic>N</italic>-(4-Butoxyphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>11</bold>)</title><p>Yield: 77%; mp: 174&#x02013;177 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.11 (s, 1H, NH), 8.85 (s, 1H, NH), 7.64 (d, <italic>J</italic> =
7.8 Hz, 1H, H-4), 7.49 (d, <italic>J</italic> = 9.0 Hz, 2H, H-2&#x02032;,
H-6&#x02032;), 7.38 (d, <italic>J</italic> = 8.1 Hz, 1H, H-7), 7.31
(s, 1H, H-2), 7.10 (t, <italic>J</italic> = 7.2 Hz, 1H, H-5), 7.01
(t, <italic>J</italic> = 7.5 Hz, 1H, H-6), 6.80 (d, <italic>J</italic> = 9.0 Hz, 2H, H-3&#x02032;, H-5&#x02032;), 3.91 (t, <italic>J</italic> = 6.3 Hz, 2H,OCH<sub>2</sub>), 3.76 (s, 2H, CH<sub>2</sub>), 1.71
(m, 2H, CH<sub>2</sub>), 1.45 (m, 2H, CH<sub>2</sub>), 0.92 (t, <italic>J</italic> = 7.5 Hz 3H, CH<sub>3</sub>); EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 322 (M<sup>+</sup>, 96), 131
(60), 130 (100), 109 (54); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub> [322.1681], found [322.1703].</p></sec><sec id="sec4.5.12"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(4-(octyloxy)
phenyl)acetamide (<bold>12</bold>)</title><p>Yield: 79%; M.p.: 155&#x02013;157
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.12 (s, 1H, NH), 8.87 (s, 1H, NH), 7.63 (d, <italic>J</italic> = 7.8 Hz 1H, H-4), 7.49 (d, <italic>J</italic> = 8.1 Hz,
2H, H-2&#x02032;, H-6&#x02032;), 7.38 (d, <italic>J</italic> = 8.1 Hz,
1H, H-7), 7.31 (s, 1H, H-2), 7.10 (t, <italic>J</italic> = 7.5 Hz,
1H, H-5), 7.00 (t, <italic>J</italic> = 7.5 Hz, 1H, H-6), 6.79 (d, <italic>J</italic> = 9.0 Hz, 2H, H-3&#x02032;, H-5&#x02032;), 3.91 (t, <italic>J</italic> = 6.6 Hz, 2H,OCH<sub>2</sub>), 3.76 (s, 2H, H-2&#x02033;),
1.71 (m, 2H,CH<sub>2</sub>), 1.41 (m, 2H,CH<sub>2</sub>), 1.29 (m,
8H, CH<sub>2,</sub> CH<sub>2,</sub> CH<sub>2,</sub> CH<sub>2</sub>), 0.85 (m, 3H, CH<sub>3</sub>); EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 378 (M<sup>+</sup>, 74), 131 (71), 130
(100), 109 (65), HREI-MS <italic>m</italic>/<italic>z</italic>: calcd
for C<sub>16</sub>H<sub>13</sub>BrN<sub>2</sub>O [328.0211], found
[328.0233].</p></sec><sec id="sec4.5.13"><title><italic>N</italic>-(4-Bromophenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>13</bold>)</title><p>Yield: 62%; mp: 196&#x02013;198 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.14 (s, 1H, NH), 9.19 (s, 1H, NH), 7.60 (m, 3H, H-4, H-3&#x02032;,
H-5&#x02032;), 7.41 (m, 3H, H-2&#x02032;, H-6&#x02032;, H-7), 7.32 (s,
1H, H-2), 7.08 (m, 1H, H-5), 7.01 (m, 1H, H-6), 3.80 (s, 2H, H-2&#x02033;); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4;
205.9, 170.4, 139.6, 132.2, 128.3, 124.6, 122.1, 121.7, 119.6, 119.3,
115.7, 112.0, 109.4, 34.9; EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 328 (M<sup>+</sup>, 39), 330 (M<sup>+2</sup>, 7),
130 (100), 103 (11.2), 77 (9); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>13</sub>BrN<sub>2</sub>O [328.0211], found [328.0202].</p></sec><sec id="sec4.5.14"><title><italic>N</italic>-(3-Bromophenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>14</bold>)</title><p>Yield: 58%; mp: 133&#x02013;135 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.14 (s, 1H, NH), 9.22 (s, 1H, NH), 8.03 (s, 1H, H-2&#x02032;), 7.62
(d, <italic>J</italic> = 7.8 Hz, 1H, H-4&#x02032;), 7.49 (m, 1H, H-6&#x02032;),
7.38 (d, <italic>J</italic> = 8.1 Hz, 1H, H-7), 7.32 (s, 1H, H-2),
7.19 (m, 2H, H-4, H-5&#x02032;), 7.10 (t, <italic>J</italic> = 7.8
Hz, 1H, H-5), 7.01 (t, <italic>J</italic> = 8.1 Hz, 1H, H-6), 3.81
(s, 2H, H-2&#x02033;); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 170.0, 140.9, 136.0, 130.6, 127.1, 125.5,
123.8, 121.4, 121.3, 120.9, 118.5, 118.3, 117.7, 111.3, 108.1, 33.7;
EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 328 (M<sup>+</sup>, 56), 330 (M<sup>+2</sup>, 9), 130 (100), 103 (17); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>13</sub>BrN<sub>2</sub>O [328.0211], found [328.0233].</p></sec><sec id="sec4.5.15"><title><italic>N</italic>-(4-Fluorophenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>15</bold>)</title><p>Yield: 76%; mp: 108&#x02013;110 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.14 (s, 1H, NH), 9.29 (s, 1H, NH), 7.69 (m, 1H, H-3&#x02032;), 7.64
(m, 1H, H-5&#x02032;), 7.39 (d, <italic>J</italic> = 8.5 Hz, 1H, H-4),
7.32 (s, 1H, H-2), 7.69 (m, 2H, H-2&#x02032;, H-6&#x02032;), 7.12 (m,
1H, H-5), 7.02 (m, 1H, H-6), 6.77 (m, 1H, H-7), 3.78 (s, 2H, H-2&#x02033;); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4;
169.5, 157.1, 138.5, 136.0, 130.0, 127.2, 123.8, 120.9, 119.9, 118.6,
118.3, 111.3, 110.5, 108.5, 101.8, 54.9, 33.8, 15.5; EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 268 (M<sup>+</sup>, 68), 157 (2), 130 (100); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>13</sub>FN<sub>2</sub>O [268.1012],
found [268.1003].</p></sec><sec id="sec4.5.16"><title><italic>N</italic>-(3-Fluorophenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>16</bold>)</title><p>Yield: 91%; mp: 148&#x02013;150 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.13 (s, 1H, NH), 9.10 (s, 1H, NH), 7.61 (m, 3H, H-2&#x02032;, H-4&#x02032;,
H-4), 7.38 (d, <italic>J</italic> = 8.1 Hz, 1H, H-7), 7.31 (s, 1H,
H-2), 7.09 (t, <italic>J</italic> = 7.8 Hz, 1H, H-5), 7.02 (m, 3H,
H-6, H-5&#x02032;, H-6&#x02032;), 3.79 (s, 2H, H-2&#x02033;); EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 268 (M<sup>+</sup>, 100), 157 (7), 130 (100); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>13</sub>FN<sub>2</sub>O [268.1012],
found [268.1022].</p></sec><sec id="sec4.5.17"><title><italic>N</italic>-(2,4-Difluorophenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide (<bold>17</bold>)</title><p>Yield:
72%;mp: 133&#x02013;135
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.19 (s, 1H, NH), 8.69 (s, 1H, NH), 8.14 (m, 1H,
H-5&#x02032;), 7.64 (d, <italic>J</italic> = 7.8 Hz, 1H, H-6&#x02032;),
7.38 (m, 2H, H-2, H-4), 7.10 (t, <italic>J</italic> = 7.5 Hz, 1H,
H-5), 7.04 (m, 1H, H-6), 6.95 (m, 2H, H-3&#x02032;, H-7), 3.89 (s,
2H, H-2&#x02033;); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 170.0, 136.0, 127.1, 125.6, 130.0, 127.2,
123.8, 120.9, 119.9, 118.6, 118.3, 111.3, 110.5, 108.5, 101.8, 54.9,
33.8, 15.5; EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.):
286 (M<sup>+</sup>, 17), 130 (100), 77 (18); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>12</sub>FN<sub>2</sub>O [286.0918], found [286.0912].</p></sec><sec id="sec4.5.18"><title><italic>N</italic>-(3,4-Difluorophenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide (<bold>18</bold>)</title><p>Yield:
78%; mp:
100&#x02013;102 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.15 (s, 1H, NH), 9.30 (s, 1H,
NH), 7.84 (m, 1H, H-5&#x02032;), 7.62 (d, <italic>J</italic> = 7.8
Hz, 1H, H-4), 7.38 (d, <italic>J</italic> = 8.1 Hz, 1H, H-7), 7.31
(s, 1H, H-2), 7.24 (m, 1H, H-2&#x02032;), 7.18 (m, 1H, H-6&#x02032;),
7.14 (m, 1H, H-5), 7.01 (t, <italic>J</italic> = 7.8 Hz, 1H, H-6),
3.80 (s, 2H, H-2&#x02033;), EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 286 (M<sup>+</sup>, 92), 131 (63), 130 (100); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O [286.0918], found [286.0943].</p></sec><sec id="sec4.5.19"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(3-iodophenyl)acetamide
(<bold>19</bold>)</title><p>Yield: 64%; mp: 136&#x02013;138 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.13 (s, 1H, NH), 9.15 (s, 1H, NH), 8.18 (s, 1H, H-2&#x02032;), 7.63
(d, <italic>J</italic> = 7.8 Hz, 1H, H-4&#x02032;), 7.54 (d, <italic>J</italic> = 7.5 Hz, 1H, H-6&#x02032;), 7.38 (d, <italic>J</italic> = 7.8 Hz, 1H, H-4), 7.32 (s, 1H, H-2), 7.07 (m, 4H, H-5&#x02032;,
H-5, H-6, H-7), 3.81 (s, 2H, H-2&#x02033;), EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 376 (M<sup>+</sup>, 95), 131
(42), 130 (100), HREI-MS <italic>m</italic>/<italic>z</italic>: calcd
for C<sub>16</sub>H<sub>13</sub>IN<sub>2</sub>O [376.0073], found
[376.0032].</p></sec><sec id="sec4.5.20"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(4-iodophenyl)acetamide
(<bold>20</bold>)</title><p>Yield: 16%; mp: 211&#x02013;213 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4;
10.13 (s, 1H, NH), 9.16 (s, 1H, NH), 7.60 (m, 3H, H-6&#x02032;, H-2&#x02032;,
H-4), 7.46 (d, <italic>J</italic> = 9.0 Hz, 2H, H-3&#x02032;, H-5&#x02032;),
7.39 (d, <italic>J</italic> = 8.1 Hz, 1H, H-7), 7.31 (s, 1H, H-2),
7.09 (t, <italic>J</italic> = 7.5 Hz, 1H, H-5), 7.01 (t, <italic>J</italic> = 7.5 Hz, 1H, H-6), 3.80 (s, 2H, H-2&#x02033;); EI-MS <italic>m/z</italic> (% rel. abund.): 376 (M<sup>+</sup>, 10), 218 (3), 130 (100); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>13</sub>IN<sub>2</sub>O [376.0073], found [376.0052].</p></sec><sec id="sec4.5.21"><title><italic>N</italic>-(4-Chlorophenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>21</bold>)</title><p>Yield: 56%; mp: 161&#x02013;163 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 10.13 (s, 1H, NH), 9.18 (s, 1H, NH), 7.64 (m, 3H,
H-5&#x02032;, H-3&#x02032;, H-4), 7.38 (d, <italic>J</italic> = 8.1
Hz, 1H, H-7), 7.32 (s, 1H, H-2), 7.25 (d, <italic>J</italic> = 9.0
Hz, 2H, H-2&#x02032;, H-6&#x02032;), 7.10 (t, <italic>J</italic> = 7.2
Hz, 1H, H-5), 7.02 (t, <italic>J</italic> = 7.5 Hz, 1H, H-6), 3.80
(s, 2H, H-2&#x02033;); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub><italic>6</italic></sub>): &#x003b4; 169.8, 138.3, 136.1, 128.5,
127.2, 126.5, 123.9, 121.0, 120.6, 118.6, 118.4, 111.4, 108.3, 33.8;
EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 283 (M<sup>+</sup>, 16), 285 (M<sup>+2</sup>, 4), 130 (100), 77(23); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>16</sub>H<sub>13</sub>ClN<sub>2</sub>O [284.0716], found [284.0724].</p></sec><sec id="sec4.5.22"><title><italic>N</italic>-(5-Chloro-2-methylphenyl)-2-(1<italic>H</italic>-indol-3-yl)acetamide
(<bold>22</bold>)</title><p>Yield: 13%; mp:
201&#x02013;203 &#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.26 (s, 1H, NH), 8.20 (s, 1H,
NH), 8.01 (s, 1H, H-6&#x02032;), 7.64 (d, <italic>J</italic> = 7.8
Hz, 1H, H-4&#x02032;), 7.43 (m, 2H, H-4, H-2), 7.10 (m, 3H, H-5, H-6,
H-3&#x02032;), 6.98 (m, 1H, H-7), 3.88 (s, 2H, H-2&#x02033;), 1.88 (s,
3H,CH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 169.9, 137.7, 136.1, 131.6, 129.7, 129.4,
127.1, 124.2, 124.0, 123.4, 121.0, 118.5, 118.4, 111.3, 108.5, 33.1,
17.1; EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.):
298 (M<sup>+</sup>, 7), 300 (M<sup>+2</sup>, 2), 130 (100), 76 (56);
HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>17</sub>H<sub>15</sub>ClN<sub>2</sub>O [298.0873], found [298.0873].</p></sec><sec id="sec4.5.23"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(3-(methylthio)
phenyl)acetamide (<bold>23</bold>)</title><p>Yield: 71%; mp: 123&#x02013;125
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.13 (s, 1H, NH), 9.06 (s, 1H, NH), 7.66 (m, 1H,
H-6&#x02032;), 7.63(d, <italic>J</italic> = 8.1 Hz, 1H, H-4), 7.38
(d, <italic>J</italic> = 8.7 Hz, 1H, H-7), 7.35 (s, 1H, H-2), 7.31(m,
1H, H-2&#x02032;), 7.18 (t, <italic>J</italic> = 8.1 Hz, 1H, H-5&#x02032;),
7.07 (m, 1H, H-5), 7.01 (m, 1H, H-6), 6.91 (m, 1H, H-4&#x02032;), 3.80
(s, 2H, H-2&#x02033;), 2.42 (s, 3H, SCH<sub>3</sub>); <sup>13</sup>C NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>): &#x003b4; 169.5,
157.1, 138.5, 136.0, 130.0, 127.2, 123.8, 120.9, 119.9, 118.6, 118.3,
111.3, 110.5, 108.5, 101.8, 54.9, 33.8, 15.5; EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 296 (M<sup>+</sup>, 9), 130
(100), 77 (28); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd
for C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>OS [296.0983], found
[296.0970].</p></sec><sec id="sec4.5.24"><title>2-(1<italic>H</italic>-Indol-3-yl)-<italic>N</italic>-(4-(methylthio)
phenyl)acetamide (<bold>24</bold>)</title><p>Yield: 86%; mp: 184&#x02013;186
&#x000b0;C, <sup>1</sup>H NMR (300 MHz, acetone-<italic>d</italic><sub>6</sub>): &#x003b4; 10.12 (s, 1H, NH), 9.05 (s, 1H, NH), 7.63 (d, <italic>J</italic> = 7.8 Hz, 1H, H-4), 7.58 (d, <italic>J</italic> = 8.7
Hz, 2H, H-2&#x02032;, H-6&#x02032;), 7.38(d, <italic>J</italic> = 8.1
Hz, 1H, H-7), 7.31 (s, 1H, H-2), 7.18(m, 2H, H-3&#x02032;, H-5&#x02032;),
7.07 (m, 1H, H-5), 7.01 (m, 1H, H-6), 3.79 (s, 2H, H-2&#x02033;), 2.42
(s, 3H, SCH<sub>3</sub>); EI-MS <italic>m</italic>/<italic>z</italic> (% rel. abund.): 296 (M<sup>+</sup>, 11), 130 (100), 77 (27); HREI-MS <italic>m</italic>/<italic>z</italic>: calcd for C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>OS [296.0983], found [296.0976].</p></sec></sec></sec></body><back><notes notes-type="COI-statement" id="NOTES-d7e3566-autogenerated"><p>The authors declare
no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>The authors are thankful to the Pakistan Academy
of Sciences,
Pakistan, for providing financial support to Project No. (5-9/PAS/440).</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Piero</surname><given-names>M. N.</given-names></name>; <name><surname>Nzaro</surname><given-names>G. M.</given-names></name>; <name><surname>Njagi</surname><given-names>J. M.</given-names></name>
<article-title>Diabetes
mellitus-a devastating metabolic
disorder</article-title>. <source>Asian J. Biomed. Pharm. Sci.</source>
<year>2014</year>, <volume>4</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.15272/ajbps.v4i40.645</pub-id>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Adeghate</surname><given-names>E.</given-names></name>
<article-title>Diabetes mellitus-multifactorial
in aetiology and global in prevalence</article-title>. <source>Arch.
Physiol. Biochem.</source>
<year>2001</year>, <volume>109</volume>, <fpage>197</fpage>&#x02013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1076/apab.109.3.197.11588</pub-id>.<pub-id pub-id-type="pmid">11880920</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Adeghate</surname><given-names>E.</given-names></name>; <name><surname>Schattner</surname><given-names>P.</given-names></name>; <name><surname>Dunn</surname><given-names>E.</given-names></name>
<article-title>An update on the etiology and epidemiology
of diabetes mellitus</article-title>. <source>Ann. NY Acad. Sci.</source>
<year>2006</year>, <volume>1084</volume>, <fpage>1</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1372.029</pub-id>.<pub-id pub-id-type="pmid">17151290</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Alam</surname><given-names>F.</given-names></name>; <name><surname>Shafique</surname><given-names>Z.</given-names></name>; <name><surname>Amjad</surname><given-names>S. T.</given-names></name>; <name><surname>Bin Asad</surname><given-names>M. H. H.</given-names></name>
<article-title>Enzymes
inhibitors
from natural sources with antidiabetic activity: A review</article-title>. <source>Phytother. Res.</source>
<year>2019</year>, <volume>33</volume>, <fpage>41</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6211</pub-id>.<pub-id pub-id-type="pmid">30417583</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Tiwari</surname><given-names>S. P.</given-names></name>; <name><surname>Srivastava</surname><given-names>R.</given-names></name>; <name><surname>Singh</surname><given-names>C. S.</given-names></name>; <name><surname>Shukla</surname><given-names>K.</given-names></name>; <name><surname>Singh</surname><given-names>R. K.</given-names></name>; <name><surname>Singh</surname><given-names>P.</given-names></name>; <name><surname>Singh</surname><given-names>R.</given-names></name>; <name><surname>Singh</surname><given-names>N. L.</given-names></name>; <name><surname>Sharma</surname><given-names>R.</given-names></name>
<article-title>Amylases:
An overview with special reference to <italic>&#x003b1;-</italic>amylase</article-title>. <source>J. Glob. Biosci.</source>
<year>2015</year>, <volume>4</volume>, <fpage>1886</fpage>&#x02013;<lpage>1901</lpage>.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Agarwal</surname><given-names>P.</given-names></name>; <name><surname>Gupta</surname><given-names>R.</given-names></name>
<article-title><italic>&#x003b1;</italic>-Amylase inhibition can treat diabetes mellitus</article-title>. <source>Res. Rev. J. Med. Heal. Sci.</source>
<year>2016</year>, <volume>5</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Lee</surname><given-names>H. J.</given-names></name>; <name><surname>Seo</surname><given-names>H. I.</given-names></name>; <name><surname>Cha</surname><given-names>H. Y.</given-names></name>; <name><surname>Yang</surname><given-names>Y. J.</given-names></name>; <name><surname>Kwon</surname><given-names>S. H.</given-names></name>; <name><surname>Yang</surname><given-names>S. J.</given-names></name>
<article-title>Diabetes and Alzheimer&#x02019;s disease: mechanisms
and nutritional aspects</article-title>. <source>Clin. Nutr. Res.</source>
<year>2018</year>, <volume>7</volume>, <fpage>229</fpage>&#x02013;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.7762/cnr.2018.7.4.229</pub-id>.<pub-id pub-id-type="pmid">30406052</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Esposito</surname><given-names>K.</given-names></name>; <name><surname>Nappo</surname><given-names>F.</given-names></name>; <name><surname>Marfella</surname><given-names>R.</given-names></name>; <name><surname>Giugliano</surname><given-names>G.</given-names></name>; <name><surname>Giugliano</surname><given-names>F.</given-names></name>; <name><surname>Ciotola</surname><given-names>M.</given-names></name>; <name><surname>Giugliano</surname><given-names>D.</given-names></name>; et al. <article-title>Inflammatory cytokine concentrations are acutely increased by hyperglycemia
in humans: role of oxidative stress</article-title>. <source>Circulation</source>
<year>2002</year>, <volume>106</volume>, <fpage>2067</fpage>&#x02013;<lpage>2072</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000034509.14906.AE</pub-id>.<pub-id pub-id-type="pmid">12379575</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Tundis</surname><given-names>R.</given-names></name>; <name><surname>Loizzo</surname><given-names>M. R.</given-names></name>; <name><surname>Menichini</surname><given-names>F.</given-names></name>
<article-title>Natural products
as <italic>&#x003b1;</italic>-amylase and <italic>&#x003b1;</italic>-glucosidase
inhibitors and
their hypoglycemic potential in the treatment of diabetes: An update</article-title>. <source>Mini-Rev. Med. Chem.</source>
<year>2010</year>, <volume>10</volume>, <fpage>315</fpage>&#x02013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.2174/138955710791331007</pub-id>.<pub-id pub-id-type="pmid">20470247</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Nair</surname><given-names>S. S.</given-names></name>; <name><surname>Kavrekar</surname><given-names>V.</given-names></name>; <name><surname>Mishra</surname><given-names>A.</given-names></name>
<article-title><italic>In
vitro</italic> studies
on <italic>&#x003b1;</italic>-amylase and <italic>&#x003b1;</italic>-glucosidase
inhibitory activities of selected plant extracts</article-title>. <source>Eur. J. Exp. Biol.</source>
<year>2013</year>, <volume>3</volume>, <fpage>128</fpage>&#x02013;<lpage>132</lpage>.</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Chen</surname><given-names>N.</given-names></name>; <name><surname>Karantza-Wadsworth</surname><given-names>V.</given-names></name>
<article-title>Role and regulation of autophagy in cancer</article-title>. <source>Biochim. Biophys. Acta</source>
<year>2009</year>, <volume>1793</volume>, <fpage>1516</fpage>&#x02013;<lpage>1523</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.12.013</pub-id>.<pub-id pub-id-type="pmid">19167434</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Gonzalez</surname><given-names>C. D.</given-names></name>; <name><surname>Lee</surname><given-names>Myung-Shik.</given-names></name>; <name><surname>Marchetti</surname><given-names>P.</given-names></name>; <name><surname>Pietropaolo</surname><given-names>M.</given-names></name>; <name><surname>Towns</surname><given-names>R.</given-names></name>; <name><surname>Vaccaro</surname><given-names>M. I.</given-names></name>; <name><surname>Watada</surname><given-names>H.</given-names></name>; <name><surname>Wiley</surname><given-names>J. W.</given-names></name>
<article-title>The emerging
role of autophagy in the pathophysiology of diabetes mellitus</article-title>. <source>Autophagy</source>
<year>2011</year>, <volume>7</volume>, <fpage>2</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.4161/auto.7.1.13044</pub-id>.<pub-id pub-id-type="pmid">20935516</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Hara</surname><given-names>T.</given-names></name>; <name><surname>Nakamura</surname><given-names>K.</given-names></name>; <name><surname>Matsui</surname><given-names>M.</given-names></name>; <name><surname>Yamamoto</surname><given-names>A.</given-names></name>; <name><surname>Nakahara</surname><given-names>Y.</given-names></name>; <name><surname>Suzuki-Migishima</surname><given-names>R.</given-names></name>; <name><surname>Yokoyama</surname><given-names>M.</given-names></name>; <name><surname>Mishima</surname><given-names>K.</given-names></name>; <name><surname>Saito</surname><given-names>I.</given-names></name>; <name><surname>Okano</surname><given-names>H.</given-names></name>; <name><surname>Mizushima</surname><given-names>N.</given-names></name>
<article-title>Suppression of basal autophagy in
neural cells causes neurodegenerative disease in mice</article-title>. <source>Nature</source>
<year>2006</year>, <volume>441</volume>, <fpage>885</fpage>&#x02013;<lpage>889</lpage>. <pub-id pub-id-type="doi">10.1038/nature04724</pub-id>.<pub-id pub-id-type="pmid">16625204</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Krakauer</surname><given-names>T.</given-names></name>
<article-title>Inflammasome,
mTORC1 activation, and metabolic derangement contribute to the susceptibility
of diabetics to infections</article-title>. <source>Med. Hypotheses</source>
<year>2015</year>, <volume>85</volume>, <fpage>997</fpage>&#x02013;<lpage>1001</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2015.08.019</pub-id>.<pub-id pub-id-type="pmid">26384528</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Peng</surname><given-names>T.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>; <name><surname>Zheng</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Jiang</surname><given-names>N.</given-names></name>; <name><surname>Cheng</surname><given-names>X.</given-names></name>; <name><surname>Lai</surname><given-names>X.</given-names></name>; <name><surname>Shunnar</surname><given-names>A.</given-names></name>; <name><surname>Singh</surname><given-names>M.</given-names></name>; <name><surname>Riordan</surname><given-names>N.</given-names></name>; <name><surname>Bogin</surname><given-names>V.</given-names></name>; <name><surname>Tong</surname><given-names>N.</given-names></name>; <name><surname>Min</surname><given-names>W. P.</given-names></name>
<article-title>Prevention of hyperglycemia-induced
myocardial apoptosis
by gene silencing of Toll-like receptor-4</article-title>. <source>J.
Transl. Med.</source>
<year>2010</year>, <volume>8</volume>, <elocation-id>133</elocation-id><pub-id pub-id-type="doi">10.1186/1479-5876-8-133</pub-id>.<pub-id pub-id-type="pmid">21159162</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Bajaj</surname><given-names>S.</given-names></name>; <name><surname>Khan</surname><given-names>A.</given-names></name>
<article-title>Antioxidants and diabetes</article-title>. <source>Indian J. Endoc.
Met.</source>
<year>2012</year>, <volume>16</volume>, <fpage>S267</fpage>&#x02013;<lpage>S271</lpage>. <pub-id pub-id-type="doi">10.4103/2230-8210.104057</pub-id>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Khan</surname><given-names>K. M.</given-names></name>; <name><surname>Khan</surname><given-names>A.</given-names></name>; <name><surname>Taha</surname><given-names>M.</given-names></name>; <name><surname>Salar</surname><given-names>U.</given-names></name>; <name><surname>Hameed</surname><given-names>A.</given-names></name>; <name><surname>Ismail</surname><given-names>N. H.</given-names></name>; <name><surname>Jamil</surname><given-names>W.</given-names></name>; <name><surname>Saad</surname><given-names>S. M.</given-names></name>; <name><surname>Perveen</surname><given-names>S.</given-names></name>; <name><surname>Kashif</surname><given-names>S. M.</given-names></name>
<article-title>Synthesis of 4-amino-1,5-dimethyl-2-phenylpyrazolone
derivatives and their antioxidant activity</article-title>. <source>J. Chem. Soc. Pak.</source>
<year>2015</year>, <volume>37</volume>, <fpage>802</fpage>&#x02013;<lpage>810</lpage>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Qurat-ul-ain</surname></name>; <name><surname>Perveen</surname><given-names>S.</given-names></name>; <name><surname>Muhammad</surname><given-names>M. T.</given-names></name>; <name><surname>Yousuf</surname><given-names>S.</given-names></name>; <name><surname>Khan</surname><given-names>K. M.</given-names></name>; <name><surname>Choudhary</surname><given-names>M. I.</given-names></name>
<article-title>Synthetic
4,4&#x02032;-{(arylmethylene)}<italic>bis</italic>(1<italic>H</italic>-pyrazol-5-ols): Efficient radical scavengers</article-title>. <source>J. Chem. Soc. Pak.</source>
<year>2018</year>, <volume>40</volume>, <fpage>563</fpage>&#x02013;<lpage>567</lpage>.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Ahad</surname><given-names>G.</given-names></name>; <name><surname>Khan</surname><given-names>M.</given-names></name>; <name><surname>Khan</surname><given-names>A.</given-names></name>; <name><surname>Ibrahim</surname><given-names>M.</given-names></name>; <name><surname>Salar</surname><given-names>U.</given-names></name>; <name><surname>Kanwal</surname></name>; <name><surname>Khan</surname><given-names>K. M.</given-names></name>; <name><surname>Perveen</surname><given-names>S.</given-names></name>
<article-title>Synthesis, structural characterization, and antioxidant
activities of 2,4-dinitrophenyl-hydrazone derivatives</article-title>. <source>J. Chem. Soc. Pak.</source>
<year>2018</year>, <volume>40</volume>, <fpage>961</fpage>&#x02013;<lpage>973</lpage>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Kohnert</surname><given-names>K. D.</given-names></name>; <name><surname>Freyse</surname><given-names>E. J.</given-names></name>; <name><surname>Salzsieder</surname><given-names>E.</given-names></name>
<article-title>Glycaemic variability and pancreatic <italic>&#x003b2;</italic>-cell dysfunction</article-title>. <source>Curr. Diab.
Rev.</source>
<year>2012</year>, <volume>8</volume>, <fpage>345</fpage>&#x02013;<lpage>354</lpage>. <pub-id pub-id-type="doi">10.2174/157339912802083513</pub-id>.</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Liang</surname><given-names>W.</given-names></name>; <name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Zheng</surname><given-names>D.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Song</surname><given-names>M.</given-names></name>; <name><surname>Mo</surname><given-names>L.</given-names></name>; <name><surname>Feng</surname><given-names>L.</given-names></name>; <name><surname>Lan</surname><given-names>J.</given-names></name>
<article-title>A novel damage
mechanism: Contribution
of the interaction between necroptosis and ROS to high glucose-induced
injury and inflammation in H9c2 cardiac cells</article-title>. <source>Int. J. Mol. Med.</source>
<year>2017</year>, <volume>40</volume>, <fpage>201</fpage>&#x02013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2017.3006</pub-id>.<pub-id pub-id-type="pmid">28560421</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Rosa</surname><given-names>M. D.</given-names></name>; <name><surname>Distefano</surname><given-names>G.</given-names></name>; <name><surname>Gagliano</surname><given-names>C.</given-names></name>; <name><surname>Rusciano</surname><given-names>D.</given-names></name>; <name><surname>Malaguarnera</surname><given-names>L.</given-names></name>
<article-title>Autophagy
in diabetic retinopathy</article-title>. <source>Curr. Neuropharm.</source>
<year>2016</year>, <volume>14</volume>, <fpage>810</fpage>&#x02013;<lpage>825</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X14666160321122900</pub-id>.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Epstein</surname><given-names>E.</given-names></name>; <name><surname>Chen</surname><given-names>K. H.</given-names></name>; <name><surname>Cohen</surname><given-names>J. D.</given-names></name>
<article-title>Identification
of indole-3-butyric
acid as an endogenous constituent of maize kernels and leaves</article-title>. <source>Pl. Growth Regul.</source>
<year>1989</year>, <volume>8</volume>, <fpage>215</fpage>&#x02013;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1007/BF00025391</pub-id>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="book" id="cit24"><person-group person-group-type="allauthors"><name><surname>Barden</surname><given-names>T. C.</given-names></name></person-group><source>Indoles: Industrial,
Agricultural and Over-the-Counter Uses Heterocyclic Scaffolds II:
Reactions and applications of Indoles</source>; <publisher-name>Academic
Press: Springer</publisher-name>, <year>2010</year>; pp <fpage>31</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Shaikh</surname><given-names>A.
C.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>An easy and
efficient synthesis of <italic>bis-</italic>indolyl methanes
and tetraindolyl methane Troger&#x02032;s Base catalyzed by AgBF<sub>4</sub></article-title>. <source>J. Chin. Chem. Soc.</source>
<year>2011</year>, <volume>58</volume>, <fpage>899</fpage>&#x02013;<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1002/jccs.201190142</pub-id>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Sharma</surname><given-names>V.</given-names></name>; <name><surname>Kumar</surname><given-names>P.</given-names></name>; <name><surname>Pathak</surname><given-names>D.</given-names></name>
<article-title>Biological importance of the indole
nucleus in recent years: A comprehensive review</article-title>. <source>J. Heterocycl. Chem.</source>
<year>2010</year>, <volume>47</volume>, <fpage>491</fpage>&#x02013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1002/jhet.349</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Liu</surname><given-names>X. G.</given-names></name>; <name><surname>Li</surname><given-names>Z. H.</given-names></name>; <name><surname>Xie</surname><given-names>J. W.</given-names></name>; <name><surname>Liu</surname><given-names>P.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Dai</surname><given-names>B.</given-names></name>
<article-title>Copper-catalyzed synthesis of 2,3-disubstituted
indoles from <italic>ortho</italic>-haloanilines and <italic>&#x003b2;</italic>-keto esters/<italic>&#x003b2;</italic>-diketone</article-title>. <source>Tetrahedron</source>
<year>2016</year>, <volume>72</volume>, <fpage>653</fpage>&#x02013;<lpage>657</lpage>. <pub-id pub-id-type="doi">10.1016/j.tet.2015.12.006</pub-id>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Shafakat
Ali</surname><given-names>N. A.</given-names></name>; <name><surname>Ahmad Dar</surname><given-names>B.</given-names></name>; <name><surname>Pradhan</surname><given-names>V.</given-names></name>; <name><surname>Farooqui</surname><given-names>M.</given-names></name>
<article-title>Chemistry
and biology of indoles and indazoles: A mini-review</article-title>. <source>Mini Rev. Med. Chem.</source>
<year>2013</year>, <volume>13</volume>, <fpage>1792</fpage>&#x02013;<lpage>1800</lpage>. <pub-id pub-id-type="doi">10.2174/1389557511313120009</pub-id>.<pub-id pub-id-type="pmid">22625410</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Radoi</surname><given-names>V.</given-names></name>; <name><surname>Lixandru</surname><given-names>D.</given-names></name>; <name><surname>Mohora</surname><given-names>M.</given-names></name>; <name><surname>Virgolici</surname><given-names>B.</given-names></name>
<article-title>Advanced glycation
end products in diabetes mellitus: mechanism of action and focused
treatment</article-title>. <source>Proc. Rom. Acad., Ser. B</source>
<year>2012</year>, <volume>1</volume>, <fpage>9</fpage>&#x02013;<lpage>19</lpage>.</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Xing</surname><given-names>H.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Xie</surname><given-names>W.</given-names></name>; <name><surname>Zhao</surname><given-names>G.</given-names></name>
<article-title>Synthesis
and anticancer activity of novel 5-(indole-2-yl)-3-substituted 1,2,4-oxadiazoles</article-title>. <source>Drug Discovery Therapy</source>
<year>2012</year>, <volume>6</volume>, <fpage>133</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.5582/ddt.2012.v6.3.133</pub-id>.</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Radwan</surname><given-names>M. A.</given-names></name>; <name><surname>Ragab</surname><given-names>E. A.</given-names></name>; <name><surname>Sabry</surname><given-names>N. M.</given-names></name>; <name><surname>El-Shenawy</surname><given-names>S. M.</given-names></name>
<article-title>Synthesis
and biological evaluation of new 3-substituted indole derivatives
as potential anti-inflammatory and analgesic agents</article-title>. <source>Bioorg. Med. Chem.</source>
<year>2007</year>, <volume>15</volume>, <fpage>3832</fpage>&#x02013;<lpage>3841</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2007.03.024</pub-id>.<pub-id pub-id-type="pmid">17395469</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Nazir</surname><given-names>M.</given-names></name>; <name><surname>Abbasi</surname><given-names>M. A.</given-names></name>; <name><surname>Aziz-ur-Rehman</surname></name>; <name><surname>Siddiqui</surname><given-names>S. Z.</given-names></name>; <name><surname>Khan</surname><given-names>K. M.</given-names></name>; <name><surname>Kanwal</surname></name>; <name><surname>Salar</surname><given-names>U.</given-names></name>; <name><surname>Shahid</surname><given-names>M.</given-names></name>; <name><surname>Ashraf</surname><given-names>M.</given-names></name>; <name><surname>Lodhi</surname><given-names>M. A.</given-names></name>; <name><surname>Khan</surname><given-names>F. A.</given-names></name>
<article-title>New indole based
hybrid oxadiazole scaffolds with <italic>N</italic>-substituted acetamide:
As potent anti-diabetic agents</article-title>. <source>Bioorg. Chem.</source>
<year>2018</year>, <volume>81</volume>, <fpage>253</fpage>&#x02013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2018.08.010</pub-id>.<pub-id pub-id-type="pmid">30153590</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Taha</surname><given-names>M.</given-names></name>; <name><surname>Imran</surname><given-names>S.</given-names></name>; <name><surname>Rahim</surname><given-names>F.</given-names></name>; <name><surname>Wadood</surname><given-names>A.</given-names></name>; <name><surname>Khan</surname><given-names>K. M.</given-names></name>
<article-title>Oxindole
based oxadiazole hybrid analogs: Novel <italic>&#x003b1;</italic>-glucosidase
inhibitors</article-title>. <source>Bioorg. Chem.</source>
<year>2018</year>, <volume>76</volume>, <fpage>273</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2017.12.001</pub-id>.<pub-id pub-id-type="pmid">29223804</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Taha</surname><given-names>M.</given-names></name>; <name><surname>Rahim</surname><given-names>F.</given-names></name>; <name><surname>Imran</surname><given-names>S.</given-names></name>; <name><surname>Ismail</surname><given-names>N. H.</given-names></name>; <name><surname>Ullah</surname><given-names>H.</given-names></name>; <name><surname>Selvaraj</surname><given-names>M.</given-names></name>; <name><surname>Javid</surname><given-names>M. T.</given-names></name>; <name><surname>Salar</surname><given-names>U.</given-names></name>; <name><surname>Ali</surname><given-names>M.</given-names></name>; <name><surname>Khan</surname><given-names>K. M.</given-names></name>
<article-title>Synthesis, <italic>&#x003b1;</italic>-Glucosidase inhibitory
activity and <italic>in silico</italic> study of <italic>tris</italic>-indole hybrid scaffold with oxadiazole ring: As potential leads
for the management of type-II diabetes mellitus</article-title>. <source>Bioorg. Chem.</source>
<year>2017</year>, <volume>74</volume>, <fpage>30</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2017.07.009</pub-id>.<pub-id pub-id-type="pmid">28750203</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Noreen</surname><given-names>T.</given-names></name>; <name><surname>Taha</surname><given-names>M.</given-names></name>; <name><surname>Imran</surname><given-names>S.</given-names></name>; <name><surname>Chigurupati</surname><given-names>S.</given-names></name>; <name><surname>Rahim</surname><given-names>F.</given-names></name>; <name><surname>Selvaraj</surname><given-names>M.</given-names></name>; <name><surname>Ismail</surname><given-names>N. H.</given-names></name>; <name><surname>Mohammad</surname><given-names>J. I.</given-names></name>; <name><surname>Ullah</surname><given-names>H.</given-names></name>; <name><surname>Javid</surname><given-names>M. T.</given-names></name>; <name><surname>Nawaz</surname><given-names>F.</given-names></name>; <name><surname>Irshad</surname><given-names>M.</given-names></name>; <name><surname>Ali</surname><given-names>M.</given-names></name>
<article-title>Synthesis of <italic>&#x003b1;</italic>- amylase inhibitors based on
privileged indole scaffold</article-title>. <source>Bioorg. Chem.</source>
<year>2017</year>, <volume>72</volume>, <fpage>248</fpage>&#x02013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2017.04.010</pub-id>.<pub-id pub-id-type="pmid">28482265</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Kanwal</surname></name>; <name><surname>Khan</surname><given-names>K. M.</given-names></name>; <name><surname>Fatima</surname><given-names>B.</given-names></name>; <name><surname>Bano</surname><given-names>B.</given-names></name>; <name><surname>Salar</surname><given-names>U.</given-names></name>
<article-title>A facile route towards the synthesis
of 2-(1<italic>H</italic>-indol-3-yl)-acetamides using 1,1-Carbonyldiimidazole</article-title>. <source>J. Chem. Soc. Pak.</source>
<year>2016</year>, <volume>38</volume>, <fpage>771</fpage>&#x02013;<lpage>774</lpage>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Kwon</surname><given-names>Y. I.</given-names></name>; <name><surname>Apostolidis</surname><given-names>E.</given-names></name>; <name><surname>Shetty</surname><given-names>K.</given-names></name>
<article-title><italic>In vitro</italic> studies
of eggplant (<italic>Solanum melongena</italic>) phenolics as inhibitors
of key enzymes relevant for type 2 diabetes and hypertension</article-title>. <source>Biores. Technol.</source>
<year>2008</year>, <volume>99</volume>, <fpage>2981</fpage>&#x02013;<lpage>2988</lpage>. <pub-id pub-id-type="doi">10.1016/j.biortech.2007.06.035</pub-id>.</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Loh</surname><given-names>S. P.</given-names></name>; <name><surname>Hadira</surname><given-names>O.</given-names></name>
<article-title>In vitro inhibitory
potential of some plants against
key enzymes involved in hyperglycemia &#x00026; hypertension</article-title>. <source>Malaysian J. Nutr.</source>
<year>2011</year>, <volume>17</volume>, <fpage>77</fpage>&#x02013;<lpage>86</lpage>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="undeclared" id="cit39"><collab>Chemical Computing Group
Inc.</collab><article-title>Molecular Operating Environment (MOE),
2016.08</article-title>; <year>2016</year>.</mixed-citation></ref></ref-list></back></article>